Valeant Pharmaceuticals

Valeant Pharmaceuticals to acquire iNova

Monday, November 21, 2011 03:03 PM

Valeant Pharmaceuticals International has signed an agreement to acquire iNova, a private pharmaceutical group. iNova owns, develops and markets a diversified portfolio of prescription and OTC pharmaceutical products in the Asia Pacific region and South Africa.

More... »

Valeant buys Johnson & Johnson skincare unit for $345 million

Tuesday, July 19, 2011 12:57 PM

Valeant Pharmaceuticals wants to become the world's biggest player in the skincare sector in about five years, its top executive told Reuters. The company has been signaling its intent with a string of recent mid-sized acquisitions in the highly fragmented but lucrative dermatology sector.

More... »

Valeant acquires Ortho Dermatologics

Monday, July 18, 2011 10:03 AM

Valeant Pharmaceuticals International subsidiaries Valeant Pharmaceuticals North America (VPNA) and Valeant International (Barbados) SRL (VIB), have signed an agreement to acquire the assets of the Ortho Dermatologics division of Janssen Pharmaceuticals. Valeant will pay Janssen $345 million for the assets, which includes prescription brands RETIN-A MICRO, ERTACZO, and RENOVA. Total revenue for the product portfolio was approximately $150 million in 2010. The transaction is subject to certain closing conditions and regulatory approvals and is expected to be accretive in 2011.

More... »

North American pharma growing by overseas acquisitions

Tuesday, May 31, 2011 03:24 PM

European drugmakers have more competition for nearby buyouts these days, according to a report on FiercePharma. With North America's pharma companies turning to international markets for growth, they're scouting Central Europe, Eastern Europe, Turkey and the Middle East for potential generics deals, which is likely to push prices upward, experts told Dow Jones.

More... »

Valeant sets deadline for Cephalon

Thursday, April 21, 2011 12:59 PM

Canada-based Valeant Pharmaceuticals declared a May 12 deadline for its $5.7 billion bid for Cephalon and said it would walk if more than 50% of Cephalon shareholders do not consent to the offer, according to a Reuters report.

More... »

Cephalon rejects buyout, Valeant remains committed

Wednesday, April 6, 2011 11:52 AM

U.S.-based Cephalon has rejected Canadian-based Valeant Pharmaceuticals International's takeover bid, saying that the $5.7 billion offer, or $73.00 per share, is not in the best interests of shareholders, according to Pharma Times.

More... »

Pension fund sues Cephalon over Valeant buyout

Friday, April 1, 2011 01:54 PM

A Pennsylvania pension fund has filed a lawsuit and accused Cephalon officials of “failing to act” in the best interests of investors regarding a $5.7 billion buyout bid by rival Mississauga, Ontario-based Valeant Pharmaceuticals International, according to a Bloomberg report.

More... »

Valeant approaches Cephalon with buyout offer

Wednesday, March 30, 2011 01:55 PM

Valeant Pharmaceuticals International, based in Canada, has made an unsolicited bid to buy U.S.-based Cephalon, a biopharmaceutical company, for $5.7 billion.

More... »